Patents Assigned to MSD International GMBH
-
Patent number: 11883479Abstract: A treatment of cervical tumor caused by human papillomavirus (HPV) infection is disclosed. Methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection include administering a combination of a HPV-specific fusion protein and an immunomodulatory agent.Type: GrantFiled: April 26, 2021Date of Patent: January 30, 2024Assignees: GENEXINE, INC., MSD International GmbHInventors: Young Chul Sung, Jung Won Woo, Jong Sup Park, Jin Won Youn
-
Patent number: 11730748Abstract: The present invention relates to Compounds of Formula (I) or Formula (II): or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.Type: GrantFiled: November 24, 2020Date of Patent: August 22, 2023Assignee: MSD International GMBHInventors: Cyril B. Dousson, David Dukhan, Christophe C. Parsy, Stephane L. Bogen
-
Publication number: 20230083431Abstract: The invention provides compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (K-Ras) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: December 15, 2020Publication date: March 16, 2023Applicants: Merck Sharp & Dohme LLC, MSD International GMBH (Singapore Branch), Agency for Science, Technology and ResearchInventors: Nicolas C. Boyer, Michael B. Garrigou, Sookhee Nicole Ha, Chunhui Huang, Anthony W. Partridge, Tomi K. Sawyer, Pietro Aronica, Charles W. Johannes, Srinivasaraghavan Kannan, Chandra S. Verma, Tsz Ying Yuen
-
Patent number: 11605025Abstract: As a data science project goes into the production stage, model maintenance to maintain model quality and predictive accuracy becomes a concern. Manual model maintenance by data scientists can become a time- and labor-intensive process, especially for large scale data science projects. An early warning system addresses this by performing systematic statistical and algorithmic checks for prediction accuracy, stability, and model assumption validity. A diagnostic report is generated that helps data scientists to assess the health of the model and identify sources of error as needed. Well-performing models can be automatically deployed without further human intervention while poor performing models trigger a warning or alert to the data scientists for further investigation and may be removed from production until the performance issues are addressed.Type: GrantFiled: May 14, 2020Date of Patent: March 14, 2023Assignees: MSD International GmbH, MSD IT Global Innovation Center s.r.o.Inventors: Yingqi Peh, Kah Hin Chin, Shao Ying Choo, Sucitro Dwijayana Sidharta, Richard Dobis
-
Publication number: 20230027495Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.Type: ApplicationFiled: November 6, 2020Publication date: January 26, 2023Applicants: Genmab A/S, MSD International GmbHInventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
-
Publication number: 20220409724Abstract: The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof,—and the use of the combination therapies for the treatment of a cancer.Type: ApplicationFiled: October 28, 2020Publication date: December 29, 2022Applicants: Eisai R&D Management Co., Ltd., Merck Sharp & Dohme Corp., MSD International GmbHInventors: Yoichi OZAWA, Yasuhiro FUNAHASHI, Yu KATO
-
Publication number: 20220363707Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.Type: ApplicationFiled: August 5, 2019Publication date: November 17, 2022Applicants: Merck Sharp & Dohme Corp., MSD International GmbHInventors: Michelle Machacek, David Witter, Craig Gibeau, Chunhui Huang, Shuhei Kawamura, David L. Sloman, Phieng Siliphaivanh, Ryan Quiroz, Murray Wan, Sebastian Schneider, Charles S. Yeung, Michael H. Reutershan, Timothy J. Henderson, Jean-Laurent Paparin, Houcine Rahali, Jonathan M. E. Hughes, Sulagna Sanyal, Yingchun Ye, David A. Candito, Patrick S. Fier, Steven M. Silverman
-
Publication number: 20220267376Abstract: Peptidomimetic macrocycles that comprise all-D configuration ?-amino acids and bind mouse double minute 2 (MDM2 aka E3 ubiquitin-protein ligase) and MDMX (aka MDM4) are described. These all-D configuration ?-amino acid peptidomimetic macrocycles are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX thereby antagonizing MDM2 and MDMX binding to p53. These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.Type: ApplicationFiled: June 16, 2020Publication date: August 25, 2022Applicants: Merck Sharp & Dohme Corp., Agency for Science, Technology and Research, MSD International GMBH (Singapore Branch)Inventors: Pietro Aronica, Christopher J. Brown, Fernando J. Ferrer, Charles W. Johannes, Srinivasaraghavan Kannan, David P. Lane, Anthony W. Partridge, Tomi K. Sawyer, Yaw Sing Tan, Chandra S. Verma, Tsz Ying Yuen
-
Publication number: 20220088191Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.Type: ApplicationFiled: May 7, 2019Publication date: March 24, 2022Applicants: MSD International GmbHInventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
-
Publication number: 20220040214Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, Q, V, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Derivative, and methods of using the Cyclic Phosphate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.Type: ApplicationFiled: October 7, 2021Publication date: February 10, 2022Applicants: MSD International GMBH, MSD International GMBHInventors: Stephane Bogen, David Dukhan, Francois-Rene Alexandre, Rachid Rahali, Christophe Claude Parsy, Julien Milhau, Claire Pierra Rouviere, Cyril B. Dousson
-
Publication number: 20210205339Abstract: The present invention relates to Compounds of Formula (I) or Formula (II): or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.Type: ApplicationFiled: November 24, 2020Publication date: July 8, 2021Applicant: MSD International GMBHInventors: Cyril B. Dousson, David Dukhan, Christophe C. Parsy, Stephane L. Bogen
-
Patent number: 11030750Abstract: Approaches for the automatic segmentation of magnetic resonance (MR) images. Machine learning models segment images to identify image features in consecutive frames at different levels of resolution. A neural network block is applied to groups of MR images to produce primary feature maps at two or more levels of resolution. The images in a given group of MR images may correspond to a cycle and have a temporal order. A second RNN block is applied to the primary feature maps to produce two or more output tensors at corresponding levels of resolution. A segmentation block is applied to the two or more output tensors to produce a probability map for the MR images. The first neural network block may be a convolutional neural network (CNN) block. The second neural network block may be a convolutional long short-term (LSTM) block.Type: GrantFiled: May 30, 2019Date of Patent: June 8, 2021Assignees: Merck Sharp & Dohme Corp., MSD International GmbHInventors: Antong Chen, Dongqing Zhang, Ilknur Icke, Belma Dogdas, Sarayu Parimal
-
Patent number: 9573959Abstract: This invention relates to methods for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrytalline SGLT2 and (S)-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex, and intermediates useful in the preparation of the said SGLT2 inhibitor.Type: GrantFiled: March 10, 2014Date of Patent: February 21, 2017Assignee: MSD International GMBHInventors: Steven J. Brenek, Stephane Caron, Jade D. Nelson, Mark E. Webster, Rodney Matthew Weekly